MedTrace Logo

Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

NCT00606632 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2018-10-02

Study results available
· View outcomes & findings →

Summary

This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.

Conditions

Interventions

DRUG

124-Iodine-cG250 (124I-cG250)

i.v. and PET/CT scan 4+/-2 days after administration

PROCEDURE

CT

contrast enhanced CT scan

Sponsors & Collaborators

  • Heidelberg Pharma AG

    lead INDUSTRY

Principal Investigators

  • Chaitanya Divgi, MD · University of Pennsylvania

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-11-30
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00606632 on ClinicalTrials.gov